Novo can now meet the demand for Ozempic and Wegovy nationwide, the Food and Drug Administration said Friday. The ruling shows Novo’s confidence that the supply of Ozempic will be stable for now.

(Bloomberg) -- Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot CagriSema. The medicine helped patients with diabetes ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...